Transvaginal Mesh for pelvic organ prolapse in Taiwan (2004–2025): Outcomes and safety in the wake of the 2019 FDA licensing halt

作者
Tsia‐Shu Lo,Maherah Kamarudina,Louiza Erika Rellora,Chia‐Hsuan Yang,Wu‐Chiao Hsieh,Yi-Hao Lin
出处
期刊:Taiwanese Journal of Obstetrics & Gynecology [Elsevier BV]
卷期号:65 (3): 465-488
标识
DOI:10.1016/j.tjog.2025.10.009
摘要

OBJECTIVE: To review the evolution, outcomes and safety of transvaginal mesh (TVM) use for pelvic organ prolapse (POP) repair in Taiwan from January 2004 to May 2025. MATERIALS AND METHODS: A systematic literature search in PubMed using MeSH terms "transvaginal mesh" AND "Pelvic organ prolapse", yielding 856 articles. Of these 96 Taiwanese studies were included, comprising 10 prospective trials, 1 meta-analysis, and the remainder retrospective studies. A total of 88 study cases involving various mesh types were analyzed. RESULTS: Objective cure rates exceeded 90% at 1-year across most mesh types, with significant improvements in quality of life measured by validated questionnaires (POPDI-6, IIQ-7, UDI-6, PISQ-12). Mesh extrusion rates with newer generation meshes (2019-2023) ranged from 0.8% to 4.8%. Most complications, such as urinary tract infections and voiding dysfunction, were minor and manageable. Surelift, Calistar-S and MIPS, the only currently approved meshes for transvaginal use in Asia, showed promising one-year cure rates, all exceeding 92%. Surelift demonstrated superiority more than native tissue repair at 5 years, with success rates of 89.1% vs. 64.4% (p = 0.002). Older age was associated with increased risk of voiding dysfunction and recurrence (HR 1.07, if > 64 years). Obesity did not increase mesh-related complications but has greater postoperative symptom burden. Concomitant MUS effectively reduced de novo stress urinary incontinence from 31.2% to 5%. CONCLUSION: TVM continues to be a reliable and effective option for POP management. Taiwan's experience highlights the importance of proper training, patient selection, and surgical refinement in minimizing complications. Long-term follow-up and awareness of red-flag symptoms remains essential.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
郁文完成签到,获得积分10
刚刚
LLL发布了新的文献求助10
1秒前
顾矜的应助被super chan采纳,获得10
1秒前
俭朴的寇完成签到,获得积分10
1秒前
1秒前
Wang发布了新的文献求助10
1秒前
珂珂完成签到,获得积分10
2秒前
2秒前
2秒前
情怀的应助被花开的石头采纳,获得20
2秒前
3秒前
3秒前
惠的厚度完成签到,获得积分20
3秒前
锅锅发布了新的文献求助10
3秒前
热心市民小红花的应助被1122SS采纳,获得10
3秒前
墨白发布了新的文献求助10
3秒前
合适的芸遥完成签到,获得积分10
4秒前
康荣濠完成签到,获得积分10
4秒前
勤恳化蛹完成签到 ,获得积分10
5秒前
远远完成签到,获得积分10
5秒前
小二郎的应助被飞鸿影下采纳,获得10
5秒前
binbin的应助被果果123采纳,获得10
5秒前
Whisper完成签到 ,获得积分10
5秒前
6秒前
Hyper完成签到,获得积分10
6秒前
6秒前
6秒前
7秒前
王小白完成签到 ,获得积分10
7秒前
Pan完成签到,获得积分10
7秒前
8秒前
zzwwill完成签到,获得积分10
8秒前
9秒前
Kiki发布了新的文献求助10
9秒前
悠闲的自然完成签到 ,获得积分10
9秒前
恐惧完成签到,获得积分10
10秒前
张嘉仪完成签到,获得积分10
10秒前
10秒前
哈哈哈完成签到,获得积分10
10秒前
任性的牛排完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153492
求助须知:如何正确求助?哪些是违规求助? 9550166
关于积分的说明 21696892
捐赠科研通 7742051
什么是DOI,文献DOI怎么找? 3425502
关于科研通互助平台的介绍 2550620
邀请新用户注册赠送积分活动 2469156